Early goal-directed haemodynamic optimization of cerebral oxygenation in comatose survivors after cardiac arrest: the Neuroprotect post-cardiac arrest trial.


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
07 06 2019
Historique:
received: 09 10 2018
revised: 02 12 2018
accepted: 06 03 2019
pubmed: 22 3 2019
medline: 30 9 2020
entrez: 22 3 2019
Statut: ppublish

Résumé

During the first 6-12 h of intensive care unit (ICU) stay, post-cardiac arrest (CA) patients treated with a mean arterial pressure (MAP) 65 mmHg target experience a drop of the cerebral oxygenation that may cause additional cerebral damage. Therefore, we investigated whether an early goal directed haemodynamic optimization strategy (EGDHO) (MAP 85-100 mmHg, SVO2 65-75%) is safe and could improve cerebral oxygenation, reduce anoxic brain damage, and improve outcome when compared with a MAP 65 mmHg strategy. A total of 112 out-of-hospital CA patients were randomly assigned to EGDHO or MAP 65 mmHg strategies during the first 36 h of ICU stay. The primary outcome was the extent of anoxic brain damage as quantified by the percentage of voxels below an apparent diffusion coefficient (ADC) score of 650.10-6 mm2/s on diffusion weighted magnetic resonance imaging (at day 5 ± 2 post-CA). Main secondary outcome was favourable neurological outcome (CPC score 1-2) at 180 days. In patients assigned to EGDHO, MAP (P < 0.001), and cerebral oxygenation during the first 12 h of ICU stay (P = 0.04) were higher. However, the percentage of voxels below an ADC score of 650.10-6 mm2/s did not differ between both groups [16% vs. 12%, odds ratio 1.37, 95% confidence interval (CI) 0.95-0.98; P = 0.09]. Also, the number of patients with favourable neurological outcome at 180 days was similar (40% vs. 38%, odds ratio 0.98, 95% CI 0.41-2.33; P = 0.96). The number of serious adverse events was lower in patients assigned to EGDHO (P = 0.02). Targeting a higher MAP in post-CA patients was safe and improved cerebral oxygenation but did not improve the extent of anoxic brain damage or neurological outcome.

Identifiants

pubmed: 30895296
pii: 5416156
doi: 10.1093/eurheartj/ehz120
doi:

Substances chimiques

Troponin 0
Oxygen S88TT14065

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1804-1814

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Auteurs

Koen Ameloot (K)

Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, Genk, Belgium.
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.
Faculty of Medicine and Life Sciences, University Hasselt, Diepenbeek, Belgium.

Cathy De Deyne (C)

Faculty of Medicine and Life Sciences, University Hasselt, Diepenbeek, Belgium.
Department of Anesthesiology and Critical Care Medicine, Ziekenhuis Oost-Limburg, Genk, Belgium.

Ward Eertmans (W)

Faculty of Medicine and Life Sciences, University Hasselt, Diepenbeek, Belgium.
Department of Anesthesiology and Critical Care Medicine, Ziekenhuis Oost-Limburg, Genk, Belgium.

Bert Ferdinande (B)

Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, Genk, Belgium.

Matthias Dupont (M)

Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, Genk, Belgium.

Pieter-Jan Palmers (PJ)

Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, Genk, Belgium.

Tibaut Petit (T)

Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, Genk, Belgium.
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Philippe Nuyens (P)

Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, Genk, Belgium.
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Joren Maeremans (J)

Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, Genk, Belgium.
Faculty of Medicine and Life Sciences, University Hasselt, Diepenbeek, Belgium.

Joris Vundelinckx (J)

Department of Anesthesiology and Critical Care Medicine, Ziekenhuis Oost-Limburg, Genk, Belgium.

Maarten Vanhaverbeke (M)

Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Ann Belmans (A)

Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Ronald Peeters (R)

Department of Neurology, University Hospitals Leuven, Leuven, Belgium.

Philippe Demaerel (P)

Department of Neurology, University Hospitals Leuven, Leuven, Belgium.

Robin Lemmens (R)

Department of Radiology, University Hospitals Leuven, Leuven, Belgium.
VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium.
Department of Neurosciences, Experimental Neurology, and Leuven Brain Institute (LBI), KU Leuven, University of Leuven, Leuven, Belgium.

Jo Dens (J)

Department of Cardiology, Ziekenhuis Oost-Limburg, Schiepse Bos 6, Genk, Belgium.
Faculty of Medicine and Life Sciences, University Hasselt, Diepenbeek, Belgium.

Stefan Janssens (S)

Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH